Management tracks: Epizyme, Disarm, Kaleido, Selecta and more

Epigenetics company Epizyme Inc. (NASDAQ:EPZM) hired Paolo Tombesi as CFO, effective next month. He was CFO at Insmed Inc. (NASDAQ:INSM).

Disarm Therapeutics Inc. (Cambridge, Mass.), which is focused on therapies for axonal degeneration, hired Alvin Shih as president and CEO. He succeeds co-founder and chair Jason Rhodes, partner at Atlas Venture, who has been serving as acting CEO. Shih was CEO of Enzyvant Sciences GmbH (Basel, Switzerland)...